ClinicalTrials.gg
RecruitingNCT07351123Pelvis ATVUpdated Jun 8, 2026

Assessment of Treatment Variability for Pelvic Ring Fragility Fractures

An observational study in Pelvic Fractures and Fragility Fractures of the Pelvis (FFP), sponsored by University of Maryland, Baltimore. Recruiting at 1 site in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by University of Maryland, Baltimore · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 133 studies in Hip Fractures with a site in United States — 22 open to participants now, 31 under way, none of them phase 3. Hip Fractures · United States.

Planned enrollment
14th of 26
120 · median 160
Started
2026
with 5 others
Observational
26 of 133
8 open now
Primary completion
2027-08
later than 16 of 30 live
Registered
130th of 133
by date
Lead sponsor
7 of 133
University of Maryland, Baltimore

Among the 133 studies in Hip Fractures with a site in United States, this one is the 14th largest by planned enrollment of the 26 observational ones that give a count, is one of 6 that started in 2026, is one of 26 observational ones, reaches primary completion later than 16 of the 30 other live ones, and was the 130th registered.

Hip Fractures

843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.

Browse Hip Fractures studies →

Open to participants now

22 of the 133 studies in Hip Fractures with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies in Hip Fractures with a site in United States, or all of them as a file.
02

Study summary

Fragility fractures of the pelvic ring are a common injury associated with poor patient outcomes and high healthcare costs. Management of these injuries is evolving with increasing frequency of operative stabilization of the pelvic ring, despite a lack of evidence supporting operative versus nonoperative treatment. This multicenter prospective cohort study will evaluate 120 patients to determine the feasibility of a randomized controlled trial comparing operative and nonoperative treatment, by evaluating patient willingness to enroll in a trial, surgeon willingness to randomize their patients' treatment, and the completeness of data collection.

Read the detailed description

Fragility fractures of the pelvic ring are a common injury that is increasing in incidence with an aging population. These injuries are associated with high healthcare costs and poor patient outcomes, including decline in ambulatory function, decreased independence, and a one-year mortality of 11-27%. Historically, older adults with fragility fractures of the pelvis received nonoperative treatment with supportive care because operative management was deemed too invasive for this patient population. However, the development of percutaneous and less invasive surgical techniques has led to an increased frequency of operative stabilization of pelvis fractures in older adults. It is unclear if the increasing use of surgical fixation is improving outcomes for patients with pelvic fragility fractures. There are significant limitations with the current body of evidence that precludes its ability to guide clinical practice. Randomized controlled trials testing the efficacy of operative management are urgently needed to determine when surgical fixation is warranted.

Two pilot randomized controlled trials have been performed on this patient population, and both have not progressed to a definitive study citing a lack of recruitment feasibility. This is due to both the lack of agreement amongst surgeons for which patients should receive randomized treatment, as well as a lack of patient willingness to enroll in a trial. Furthermore, loss to follow up is a concern in both the orthopaedic trauma population and in older adult study patients. This prospective cohort study will evaluate 120 patients from six hospitals to determine the feasibility of a randomized controlled trial (RCT) comparing operative versus nonoperative management of fragility fractures of the pelvic ring. This will be accomplished by three aims evaluating patient willingness to enroll in a trial, surgeon willingness to randomize their patients' treatment, and the completeness of data collection.

03

Conditions studied

  • Pelvic Fractures
  • Fragility Fractures of the Pelvis (FFP)

Browse trials for

Keywords

  • Pelvic fracture
  • Fragility fracture of the pelvis
  • Pelvic ring injury
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients ≥ 60 years of age with a closed pelvic ring fracture with an anterior and posterior injury observable on x-ray or CT scan.

Eligibility criteria

The inclusion criteria are:

  1. Patient 60 years of age or older.
  2. Low energy injury mechanism.
  3. LC1 pelvis fracture (AO/OTA 61B1.1,61B2.1, or 61B3.2) confirmed with antero-posterior, inlet, and outlet pelvis radiographs, computed tomography, or magnetic resonance imaging.
  4. Fracture displacement of \<10 mm of the posterior pelvic ring on computed tomography of the pelvis.
  5. Injury occurred within 21 days of screening.

The exclusion criteria are:

  1. Patient did not ambulate prior to injury.
  2. Severely frail patients (Clinical Frailty Scale ≥7).
  3. Patient has another condition, injury, or fracture that prevents post-operative weightbearing on any extremity.
  4. Retained implants around the pelvis that precludes or limits either study treatment.
  5. Infection around the hip (soft tissue or bone).
  6. Pathologic fracture with a lytic lesion in the pelvis or sacrum that precludes internal fixation.
  7. Patient is too ill, in the judgement of the attending surgeon, for internal fixation.
  8. Patient is too ill, in the judgement of the attending surgeon, for nonoperative care.
  9. Problems, in the judgment of study personnel, with maintaining follow-up with the patient.
  10. Expected injury survival of less than 12 months.
  11. Terminal illness with expected survival of less than 12 months.
  12. Currently enrolled in a study that does not permit co-enrollment.
  13. Prior enrollment in the study.
  14. Unable to obtain due to language barriers.
  15. Unable to obtain informed consent because a legally authorized representative (LAR) was unavailable.
  16. Did not provide informed consent (declined participation).
  17. Patient or LAR not approached to participate in the trial (missed patient).
  18. Other reason to exclude the patient, as approved by the Principal Investigator.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patient

    Patients aged 60 years and older with a low energy mechanism closed pelvic ring fracture with an anterior and posterior injury observable on x-ray or CT scan

    Procedure: Surgical stabilization of pelvic fracture · Other: Closed treatment of pelvic fracture

Interventions

  • ProcedureSurgical stabilization of pelvic fracture

    Surgical stabilization of pelvic fracture through placement of orthopaedic hardware.

  • OtherClosed treatment of pelvic fracture

    Pelvic fracture that is treated without surgery and assessed over time through interval radiographs until fracture is healed.

06

What researchers measure

Primary outcomes

  1. Patient Willingness to Enroll in a Trial

    Willingness to enroll in a trial will be assessed as a binary variable with the central three choices representing that the participant is willing to have their treatment randomized.

    Time frame: 4 months

  2. Surgeon Willingness to Randomize Patient Treatment

    Surgeon willingness to enroll the patient in the trial will be assessed as a binary variable with the central three choices representing that the surgeon would have been willing to have their treatment decision randomized.

    Time frame: 4 months

  3. Completeness of Patient Centered Outcomes Collected

    The outcome measure completion will be assessed as a binary variable classified as either complete documentation or missing documentation.

    Time frame: 4 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The Final Research Data set of validated de-identified data will include discrete data elements supporting the primary and secondary endpoints. Demographic, injury, clinical results data will be acquired from pelvis fracture subjects. All data will be de-identified prior to receipt by the National Trauma Research Repository (NTRR).

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be made available to the research community as soon as possible, but no later than one year after publication of the initial study manuscript. All data will be kept in the NTRR for at least five years after the initial study publication.

Access criteria: All data and associated study materials will be submitted to the NTRR. The NTRR is built on the Biomedical Research Information Computing System (BRICS) platform developed by the Center for Information Technology at the National Institutes of Health (NIH). The NTRR platform and processes meet the NIH Grant Policy on Sharing of Unique Research Resources, including the Sharing of Biomedical Research Resources Principles and Guidelines for Recipients of the NIH Grants and Contracts. Data will be findable for the research community through the NTRR. The NTRR assigns a unique digital object identifier (DOI) for each data set submitted. This DOI, as a persistent unique identifier, can be used to reference the data set in manuscripts. Data stored in the NTRR meets FAIR principles (findable, accessible, interoperable, and re-usable).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Aug 2027, 15 months after the start.

Of 107 non-industry observational studies under Hip Fractures, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 65. This study's planned 15 months is below that.

Counting every sponsor, half of 124 studies reached it within 28 months; a quarter within 12 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2026
First posted
Jan 20, 2026
StartActual
May 25, 2026
Primary completionEst.
Aug 31, 2027
CompletionEst.
Sep 30, 2027
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07351123
Responsible party
Mark Gage (Associate Professor, University of Maryland, Baltimore) — Principal investigator
First posted
Jan 20, 2026
Start date
May 25, 2026
Primary completion
Aug 31, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Jun 8, 2026

Study contacts

Mark Gage, MD
Contact
mgage@som.umaryland.edu
410-328-1868
Heather Phipps, MPS
Contact
hphipps@som.umaryland.edu
Mark Gage, MD
principal investigator · University of Maryland, Baltimore

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion